Kappa myeloma antigen chimeric antigen receptors and uses thereof
AssigneeHaemaLogix Pty Ltd
InventorsKenneth Micklethwaite, Rosanne Dunn, David Gottlieb, Grant Logan
Life of this patent
Estimating the term…
Abstract
The present invention provides compositions and methods for treating KMA-expressing malignancies including chimeric antigen receptors (CARs) and T cells containing CARs (CAR T-cells). The invention also provides methods and compositions comprising CAR T-cells co-expressing other anti-tumoral agents including cytokines and antibodies.
Claims18
A chimeric antigen receptor (CAR) comprising one or more intracellular signaling domains and an extracellular antigen binding domain, wherein the extracellular antigen binding domain comprises a single chain variable fragment (scFv) that specifically binds kappa myeloma antigen (KMA) and does not bind immunoglobulin (Ig) kappa light chain associated with an Ig heavy chain, wherein the scFv comprises the VL chain and VH chain from KappaMab, wherein the VL chain comprises the VL chain of SEQ ID NO:
- 2 and the VH chain comprises the VH chain of SEQ ID NO:
- 1.
A chimeric antigen receptor (CAR) comprising one or more intracellular signaling domains and an extracellular antigen binding domain, wherein the extracellular antigen binding domain specifically recognizes kappa myeloma antigen (KMA), wherein the extracellular binding domain comprises a single chain variable fragment (scFv) that specifically recognizes KMA, wherein the scFv comprises the VL chain and VH chain from KappaMab wherein the VL chain comprises the VL chain of SEQ ID NO:
- 2 and the VH chain comprises the VH chain of SEQ ID NO:
- 1.
A method for producing a genetically modified T cell comprising introducing into a T cell an expression vector encoding a CAR comprising one or more intracellular signaling domains and an extracellular antigen binding domain, wherein the extracellular antigen binding domain specifically recognizes kappa myeloma antigen (KMA), wherein the extracellular binding domain comprises a single chain variable fragment (scFv) that specifically recognizes KMA, wherein the scFv comprises the VL chain and VH chain from KappaMab wherein the VL chain comprises the VL chain of SEQ ID NO:
- 2 and the VH chain comprises the VH chain of SEQ ID NO:
- 1.
A method of treating a KMA-expressing malignancy in a subject in need thereof comprising administering genetically modified T cells engineered to express one or more intracellular signaling domains and an extracellular antigen binding domain, wherein the extracellular antigen binding domain specifically recognizes kappa myeloma antigen (KMA), wherein the extracellular binding domain comprises a single chain variable fragment (scFv) that specifically recognizes KMA, wherein the scFv comprises the VL chain and VH chain from KappaMab wherein the VL chain comprises the VL chain of SEQ ID NO:
- 2 and the VH chain comprises the VH chain of SEQ ID NO:
- 1.
Dependencies are inferred from the claim text.